Evoke Historical Balance Sheet

EVOK Stock

USD 2.82 0.02 0.71%

Trend analysis of Evoke Pharma balance sheet accounts such as Total Current Liabilities of 10.9 T or Total Stockholder Equity of 7.4 T provides information on Evoke Pharma's total assets, liabilities, and equity, which is the actual value of Evoke Pharma to its prevalent stockholders. By breaking down trends over time using Evoke Pharma balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Evoke Pharma latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Evoke Pharma is a good buy for the upcoming year.

Evoke Pharma Inventory

467.34 Billion

Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Evoke Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.

For more information on how to buy Evoke Stock please use our How to buy in Evoke Stock guide.

About Evoke Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Evoke Pharma at a specified time, usually calculated after every quarter, six months, or one year. Evoke Pharma Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Evoke Pharma and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Evoke currently owns. An asset can also be divided into two categories, current and non-current.

Evoke Pharma Balance Sheet Chart

At this time, Evoke Pharma's Common Stock Total Equity is quite stable compared to the past year. Liabilities And Stockholders Equity is expected to rise to about 18.4 T this year, although the value of Accounts Payable will most likely fall to about 1.4 M.

Total Assets Other Current Liab Total Current Liabilities Accounts Payable Non Current Liabilities Total

Add Fundamental

Total Assets

Total assets refers to the total amount of Evoke Pharma assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Evoke Pharma books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Evoke Pharma balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Evoke Pharma are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Accounts Payable

An accounting item on the balance sheet that represents Evoke Pharma obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Evoke Pharma are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Most accounts from Evoke Pharma's balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Evoke Pharma current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Evoke Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.

For more information on how to buy Evoke Stock please use our How to buy in Evoke Stock guide.At this time, Evoke Pharma's Common Stock Total Equity is quite stable compared to the past year. Liabilities And Stockholders Equity is expected to rise to about 18.4 T this year, although the value of Accounts Payable will most likely fall to about 1.4 M.

	2022	2023	2024	2025 (projected)
Other Current Liabilities	528.1K	2.9M	10.4T	10.9T
Total Assets	11.9M	7.1M	17.5T	18.4T

Other Current Liab Total Assets

Evoke Pharma balance sheet Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Cash	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Common Stock	Short Long Term Debt Total	Long Term Debt	Other Liab	Net Tangible Assets	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Retained Earnings Total Equity	Long Term Debt Total
Total Assets		1.0	1.0	1.0	-0.21	-1.0	0.37	0.22	1.0	0.52	0.3	-0.35	1.0	1.0	1.0	1.0	-0.33	0.33	0.24	-0.05	-0.19	1.0	1.0	-0.16	-0.32	0.22
Other Current Liab	1.0		1.0	1.0	-0.21	-1.0	0.37	0.22	1.0	0.52	0.3	-0.35	1.0	1.0	1.0	1.0	-0.33	0.33	0.24	-0.05	-0.19	1.0	1.0	-0.16	-0.32	0.22
Total Current Liabilities	1.0	1.0		1.0	-0.21	-1.0	0.37	0.22	1.0	0.52	0.3	-0.35	1.0	1.0	1.0	1.0	-0.33	0.33	0.24	-0.05	-0.19	1.0	1.0	-0.16	-0.32	0.22
Total Stockholder Equity	1.0	1.0	1.0		-0.21	-1.0	0.37	0.22	1.0	0.52	0.3	-0.35	1.0	1.0	1.0	1.0	-0.33	0.33	0.24	-0.05	-0.19	1.0	1.0	-0.16	-0.32	0.22
Net Debt	-0.21	-0.21	-0.21	-0.21		0.21	-0.31	-0.92	-0.21	-0.01	-0.21	0.61	-0.21	-0.21	-0.21	-0.21	0.01	-0.05	0.11	-0.21	-0.03	-0.21	-0.21	0.08	-0.12	-0.01
Retained Earnings	-1.0	-1.0	-1.0	-1.0	0.21		-0.38	-0.22	-1.0	-0.51	-0.31	0.35	-1.0	-1.0	-1.0	-1.0	0.33	-0.34	-0.25	0.05	0.19	-1.0	-1.0	0.15	0.32	-0.23
Accounts Payable	0.37	0.37	0.37	0.37	-0.31	-0.38		0.41	0.37	0.51	0.59	-0.78	0.37	0.37	0.37	0.37	0.14	0.3	0.41	0.57	-0.74	0.37	0.37	-0.8	-0.52	0.79
Cash	0.22	0.22	0.22	0.22	-0.92	-0.22	0.41		0.22	0.17	0.07	-0.65	0.22	0.22	0.22	0.22	0.03	0.41	0.17	0.22	-0.12	0.22	0.22	-0.14	-0.05	0.16
Cash And Short Term Investments	1.0	1.0	1.0	1.0	-0.21	-1.0	0.37	0.22		0.52	0.3	-0.35	1.0	1.0	1.0	1.0	-0.33	0.33	0.24	-0.05	-0.19	1.0	1.0	-0.16	-0.32	0.22
Common Stock Total Equity	0.52	0.52	0.52	0.52	-0.01	-0.51	0.51	0.17	0.52		0.38	-0.64	0.52	0.52	0.52	0.52	0.35	0.51	0.68	-0.12	-0.77	0.52	0.52	-0.58	-0.96	0.78
Common Stock Shares Outstanding	0.3	0.3	0.3	0.3	-0.21	-0.31	0.59	0.07	0.3	0.38		-0.65	0.3	0.3	0.3	0.3	0.28	-0.35	0.24	0.17	-0.46	0.3	0.3	-0.64	-0.36	0.58
Non Current Liabilities Total	-0.35	-0.35	-0.35	-0.35	0.61	0.35	-0.78	-0.65	-0.35	-0.64	-0.65		-0.35	-0.35	-0.35	-0.35	-0.37	-0.26	-0.51	-0.29	0.7	-0.35	-0.35	0.76	0.6	-0.73
Other Current Assets	1.0	1.0	1.0	1.0	-0.21	-1.0	0.37	0.22	1.0	0.52	0.3	-0.35		1.0	1.0	1.0	-0.33	0.33	0.24	-0.05	-0.19	1.0	1.0	-0.16	-0.32	0.22
Other Stockholder Equity	1.0	1.0	1.0	1.0	-0.21	-1.0	0.37	0.22	1.0	0.52	0.3	-0.35	1.0		1.0	1.0	-0.33	0.33	0.24	-0.05	-0.19	1.0	1.0	-0.16	-0.32	0.22
Total Liab	1.0	1.0	1.0	1.0	-0.21	-1.0	0.37	0.22	1.0	0.52	0.3	-0.35	1.0	1.0		1.0	-0.33	0.33	0.24	-0.05	-0.19	1.0	1.0	-0.16	-0.32	0.22
Total Current Assets	1.0	1.0	1.0	1.0	-0.21	-1.0	0.37	0.22	1.0	0.52	0.3	-0.35	1.0	1.0	1.0		-0.33	0.33	0.24	-0.05	-0.19	1.0	1.0	-0.16	-0.32	0.22
Common Stock	-0.33	-0.33	-0.33	-0.33	0.01	0.33	0.14	0.03	-0.33	0.35	0.28	-0.37	-0.33	-0.33	-0.33	-0.33		-0.04	0.29	-0.06	-0.54	-0.33	-0.33	-0.44	-0.47	0.47
Short Long Term Debt Total	0.33	0.33	0.33	0.33	-0.05	-0.34	0.3	0.41	0.33	0.51	-0.35	-0.26	0.33	0.33	0.33	0.33	-0.04		0.66	0.04	-0.37	0.33	0.33	-0.16	-0.45	0.33
Long Term Debt	0.24	0.24	0.24	0.24	0.11	-0.25	0.41	0.17	0.24	0.68	0.24	-0.51	0.24	0.24	0.24	0.24	0.29	0.66		-0.18	-0.58	0.24	0.24	-0.47	-0.68	0.62
Other Liab	-0.05	-0.05	-0.05	-0.05	-0.21	0.05	0.57	0.22	-0.05	-0.12	0.17	-0.29	-0.05	-0.05	-0.05	-0.05	-0.06	0.04	-0.18		-0.37	-0.05	-0.05	-0.58	0.05	0.37
Net Tangible Assets	-0.19	-0.19	-0.19	-0.19	-0.03	0.19	-0.74	-0.12	-0.19	-0.77	-0.46	0.7	-0.19	-0.19	-0.19	-0.19	-0.54	-0.37	-0.58	-0.37		-0.19	-0.19	0.9	0.86	-0.95
Non Current Assets Total	1.0	1.0	1.0	1.0	-0.21	-1.0	0.37	0.22	1.0	0.52	0.3	-0.35	1.0	1.0	1.0	1.0	-0.33	0.33	0.24	-0.05	-0.19		1.0	-0.16	-0.32	0.22
Non Currrent Assets Other	1.0	1.0	1.0	1.0	-0.21	-1.0	0.37	0.22	1.0	0.52	0.3	-0.35	1.0	1.0	1.0	1.0	-0.33	0.33	0.24	-0.05	-0.19	1.0		-0.16	-0.32	0.22
Other Assets	-0.16	-0.16	-0.16	-0.16	0.08	0.15	-0.8	-0.14	-0.16	-0.58	-0.64	0.76	-0.16	-0.16	-0.16	-0.16	-0.44	-0.16	-0.47	-0.58	0.9	-0.16	-0.16		0.67	-0.91
Retained Earnings Total Equity	-0.32	-0.32	-0.32	-0.32	-0.12	0.32	-0.52	-0.05	-0.32	-0.96	-0.36	0.6	-0.32	-0.32	-0.32	-0.32	-0.47	-0.45	-0.68	0.05	0.86	-0.32	-0.32	0.67		-0.85
Long Term Debt Total	0.22	0.22	0.22	0.22	-0.01	-0.23	0.79	0.16	0.22	0.78	0.58	-0.73	0.22	0.22	0.22	0.22	0.47	0.33	0.62	0.37	-0.95	0.22	0.22	-0.91	-0.85

Click cells to compare fundamentals

Evoke Pharma Account Relationship Matchups

Evoke Pharma balance sheet Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	9.4M	10.6M	11.9M	7.1M	17.5T	18.4T
Other Current Liab	6.0M	506.9K	528.1K	2.9M	10.4T	10.9T
Total Current Liabilities	7.5M	1.4M	1.7M	9.6M	10.4T	10.9T
Total Stockholder Equity	(3.2M)	3.6M	4.1M	(2.6M)	7.0T	7.4T
Net Debt	(2.8M)	(4.1M)	(4.7M)	260.6K	(8.4M)	(8.9M)
Retained Earnings	(98.9M)	(107.4M)	(115.6M)	(123.4M)	(128.8T)	(122.4T)
Accounts Payable	1.3M	874.0K	868.3K	1.7M	2.3M	1.4M
Cash	8.1M	9.1M	9.8M	4.7M	13.6M	9.5M
Cash And Short Term Investments	8.1M	9.1M	9.8M	4.7M	13.6T	14.3T
Common Stock Shares Outstanding	177.0K	223.5K	262.0K	278.6K	1.4M	709.9K
Liabilities And Stockholders Equity	9.4M	10.6M	11.9M	7.1M	17.5T	18.4T
Non Current Liabilities Total	5.1M	5.6M	6.1M	6.6M	101.0K	95.9K
Other Current Assets	952.1K	935.3K	964.5K	932.6K	775.8B	814.6B
Other Stockholder Equity	95.7M	111.0M	119.7M	120.9M	135.8T	142.6T
Total Liab	12.6M	7.0M	7.8M	9.6M	10.5T	11.0T
Total Current Assets	9.3M	10.6M	11.7M	6.8M	17.2T	18.1T
Common Stock	2.4K	2.7K	3.3K	334.0	149.0	141.55
Short Long Term Debt Total	5.2M	5.0M	5.1M	5M	5.2M	4.2M
Net Tangible Assets	4.4M	(3.2M)	3.6M	4.1M	3.7M	4.2M
Non Current Assets Total	153.3K	12.4K	129.1K	241.6K	281.1B	295.2B
Short Term Debt	245.9K	24.9K	258.1K	5M	5.1M	5.3M
Net Invested Capital	1.9M	8.6M	9.1M	2.4M	12.0M	6.1M
Net Working Capital	1.7M	9.2M	10.1M	3.8M	6.9M	6.3M
Capital Stock	2.4K	2.7K	3.3K	334.0	149.0	141.55
Property Plant And Equipment Net	141.7K	12.4K	129.1K	0.0	154.2B	161.9B
Capital Lease Obligations	141.7K	12.4K	129.1K	0.0	160.5K	168.5K
Property Plant And Equipment Gross	141.7K	12.4K	129.1K	0.0	154.2K	161.9K

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Evoke Pharma is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Evoke Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Evoke Pharma Stock. Highlighted below are key reports to facilitate an investment decision about Evoke Pharma Stock:

How To Invest In Evoke

Details

Is Evoke Stock a good investment?

Details

What is Evoke Pharma's Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

For more information on how to buy Evoke Stock please use our How to buy in Evoke Stock guide.

You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.

Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Evoke Pharma. If investors know Evoke will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Evoke Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(2.81)

Revenue Per Share

5.38

Quarterly Revenue Growth

0.974

Return On Assets

(0.26)

Return On Equity

(2.40)

The market value of Evoke Pharma is measured differently than its book value, which is the value of Evoke that is recorded on the company's balance sheet. Investors also form their own opinion of Evoke Pharma's value that differs from its market value or its book value, called intrinsic value, which is Evoke Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Evoke Pharma's market value can be influenced by many factors that don't directly affect Evoke Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Evoke Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Evoke Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Evoke Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Evoke Historical Balance Sheet

Evoke Pharma Inventory

467.34 Billion

About Evoke Balance Sheet Analysis

Evoke Pharma Balance Sheet Chart

Total Assets

Total Current Liabilities

Accounts Payable

Evoke Pharma balance sheet Correlations

Evoke Pharma Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Evoke Pharma balance sheet Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Other Current Liab	+ 1.0	Total Assets
Total Current Liabilities	+ 1.0	Total Assets
Total Stockholder Equity	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Assets
Other Current Assets	+ 1.0	Total Assets
Other Stockholder Equity	+ 1.0	Total Assets

Non Currrent Assets Other	- 1.0	Retained Earnings
Non Current Assets Total	- 1.0	Retained Earnings
Total Current Assets	- 1.0	Retained Earnings
Total Liab	- 1.0	Retained Earnings
Other Stockholder Equity	- 1.0	Retained Earnings
Other Current Assets	- 1.0	Retained Earnings